214 related articles for article (PubMed ID: 14528284)
1. Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor I receptor.
Surmacz E
Oncogene; 2003 Sep; 22(42):6589-97. PubMed ID: 14528284
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity.
Salatino M; Schillaci R; Proietti CJ; Carnevale R; Frahm I; Molinolo AA; Iribarren A; Charreau EH; Elizalde PV
Oncogene; 2004 Jul; 23(30):5161-74. PubMed ID: 15122317
[TBL] [Abstract][Full Text] [Related]
3. Genetic blockade of the insulin-like growth factor 1 receptor for human malignancy.
Adachi Y; Lee CT; Carbone DP
Novartis Found Symp; 2004; 262():177-89; discussion 190-2, 265-8. PubMed ID: 15562829
[TBL] [Abstract][Full Text] [Related]
4. Control of apoptosis in human multiple myeloma by insulin-like growth factor I (IGF-I).
Jernberg-Wiklund H; Nilsson K
Adv Cancer Res; 2007; 97():139-65. PubMed ID: 17419944
[TBL] [Abstract][Full Text] [Related]
5. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer.
Barnes CJ; Ohshiro K; Rayala SK; El-Naggar AK; Kumar R
Clin Cancer Res; 2007 Jul; 13(14):4291-9. PubMed ID: 17634559
[TBL] [Abstract][Full Text] [Related]
6. Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin.
Zhang H; Pelzer AM; Kiang DT; Yee D
Cancer Res; 2007 Jan; 67(1):391-7. PubMed ID: 17210722
[TBL] [Abstract][Full Text] [Related]
7. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.
Burtrum D; Zhu Z; Lu D; Anderson DM; Prewett M; Pereira DS; Bassi R; Abdullah R; Hooper AT; Koo H; Jimenez X; Johnson D; Apblett R; Kussie P; Bohlen P; Witte L; Hicklin DJ; Ludwig DL
Cancer Res; 2003 Dec; 63(24):8912-21. PubMed ID: 14695208
[TBL] [Abstract][Full Text] [Related]
8. Insulin-like growth factor-I receptor blockade reduces the invasiveness of gastrointestinal cancers via blocking production of matrilysin.
Adachi Y; Li R; Yamamoto H; Min Y; Piao W; Wang Y; Imsumran A; Li H; Arimura Y; Lee CT; Imai K; Carbone DP; Shinomura Y
Carcinogenesis; 2009 Aug; 30(8):1305-13. PubMed ID: 19493905
[TBL] [Abstract][Full Text] [Related]
9. Differential mechanisms of acquired resistance to insulin-like growth factor-i receptor antibody therapy or to a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model.
Huang F; Hurlburt W; Greer A; Reeves KA; Hillerman S; Chang H; Fargnoli J; Graf Finckenstein F; Gottardis MM; Carboni JM
Cancer Res; 2010 Sep; 70(18):7221-31. PubMed ID: 20807811
[TBL] [Abstract][Full Text] [Related]
10. Differential activation of insulin receptor substrates 1 and 2 by insulin-like growth factor-activated insulin receptors.
Denley A; Carroll JM; Brierley GV; Cosgrove L; Wallace J; Forbes B; Roberts CT
Mol Cell Biol; 2007 May; 27(10):3569-77. PubMed ID: 17325037
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of the insulin-like growth factor I receptor by antisense RNA can reverse the transformed phenotype of human cervical cancer cell lines.
Nakamura K; Hongo A; Kodama J; Miyagi Y; Yoshinouchi M; Kudo T
Cancer Res; 2000 Feb; 60(3):760-5. PubMed ID: 10676665
[TBL] [Abstract][Full Text] [Related]
12. Role of estrogen receptor alpha in modulating IGF-I receptor signaling and function in breast cancer.
Surmacz E; Bartucci M
J Exp Clin Cancer Res; 2004 Sep; 23(3):385-94. PubMed ID: 15595626
[TBL] [Abstract][Full Text] [Related]
13. beta1A integrin expression is required for type 1 insulin-like growth factor receptor mitogenic and transforming activities and localization to focal contacts.
Goel HL; Breen M; Zhang J; Das I; Aznavoorian-Cheshire S; Greenberg NM; Elgavish A; Languino LR
Cancer Res; 2005 Aug; 65(15):6692-700. PubMed ID: 16061650
[TBL] [Abstract][Full Text] [Related]
14. The insulin-like growth factor-I receptor as an oncogene.
Werner H; Bruchim I
Arch Physiol Biochem; 2009 May; 115(2):58-71. PubMed ID: 19485702
[TBL] [Abstract][Full Text] [Related]
15. Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells.
Cunningham MP; Thomas H; Marks C; Green M; Fan Z; Modjtahedi H
Int J Oncol; 2008 Nov; 33(5):1107-13. PubMed ID: 18949375
[TBL] [Abstract][Full Text] [Related]
16. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review.
Ozkan EE
Mol Cell Endocrinol; 2011 Sep; 344(1-2):1-24. PubMed ID: 21782884
[TBL] [Abstract][Full Text] [Related]
17. The IGF receptor as anticancer treatment target.
Macaulay VM
Novartis Found Symp; 2004; 262():235-43; discussion 243-6, 265-8. PubMed ID: 15562833
[TBL] [Abstract][Full Text] [Related]
18. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN
Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627
[TBL] [Abstract][Full Text] [Related]
19. Insulin-Like Growth Factor (IGF) family and prostate cancer.
Gennigens C; Menetrier-Caux C; Droz JP
Crit Rev Oncol Hematol; 2006 May; 58(2):124-45. PubMed ID: 16387509
[TBL] [Abstract][Full Text] [Related]
20. [Type I insulin-like growth factor receptor antisense strategies in experimental breast cancer].
Salatino M; Schillaci R; Proietti CJ; Carnevale R; Charreau EH; Elizalde PV
Medicina (B Aires); 2004; 64(2):129-34. PubMed ID: 15628299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
